Developments in checkpoint immunotherapy

Bookmark and Share
Published: 22 Sep 2016
Views: 1326
Dr James Larkin - The Royal Marsden NHS Foundation Trust, London, UK

Dr Larkin speaks with ecancertv at WCCS 2016 about developments in checkpoint immunotherapy.

He discusses results from recent trials of single agent, combined and adjuvant immunotherapy compared to targeted therapies, with regards to overall survival, subgroups determined by biomarkers, and complementary mechanisms.

With regard to public awareness of melanoma, Dr Larkin highlights successful international campaigns and the remaining need in some populations for preventative measures to limit UV exposure.